Open access peer-reviewed chapter

A Review of Progesterone Effects on Human Melanoma Cell Growth In-Vitro

By Pandurangan Ramaraj

Submitted: August 13th 2021Reviewed: October 15th 2021Published: December 2nd 2021

DOI: 10.5772/intechopen.101239

Downloaded: 51

Abstract

Progesterone, a female sex hormone not only has a role in reproduction, but also in protecting females in melanoma. A survey of steroid hormones actions steroid hormones actions survey on melanoma cells and literature survey showed that progesterone inhibited mouse and human melanoma cell growth significantly in-vitro. Progesterone not only inhibited cell growth, but also affected adhesion and migration functions (essential for metastasis) in-vitro. This observation correlated with the clinical studies where they had shown showed an increased survival and delayed metastasis in menstruating females in melanoma. Further, progesterone level in menstruating females (1000–1500 ng/dL) compared to post-menopausal females (20–100 ng/dL) also correlated with previous clinical studies. Progesterone action on melanoma cells, as reported by other researchers also supported the findings from this lab. Hence, progesterone could be the steroid hormone protecting menstruating females in melanoma. Moreover, our recent studies showed that progesterone suppressed pro-inflammatory cytokine IL-8 secretion by the melanoma cells, which decreased melanoma cell growth in-vitro. Hence, progesterone apart from reproductive function may also be involved in protecting menstruating females in melanoma.

Keywords

  • progesterone
  • menstruating females
  • protection in melanoma
  • IL-8 secretion

1. Introduction

Skin is not only a largest organ in the body, but also an endocrine organ and a target site for other hormones [1, 2, 3]. Skin has all the elements of a functional hypothalamo-pituitary-adrenal axis [4]. So, it has CRH (corticotropic releasing hormone), POMC (pre-opiomelano cortin) and associated peptides ACTH (adreno corticotropic hormone), α-MSH (α-melanocyte stimulating hormone), β-endorphin [5]. Expression of these peptides is environmentally regulated and their dysfunction can lead to skin and systemic diseases [6]. Skin neuroendocrine system acts by preserving and maintaining the skin structural and functional integrity [7]. This network allow skin to maintain local and global homeostasis that is vital for survival [6, 7]. Skin and hair follicles not only have functional melatonin receptor, but to a larger extent serve as an extra-pineal organ to synthesize melatonin [8]. Skin has the ability to synthesize glucocorticoid from cholesterol or from steroid intermediates of systemic origin [6]. By interacting with glucocorticoid receptor, immune functions and physiological functions of epidermal, dermal and subcutaneous structures are regulated [9]. Since, synthesis and site of actions of hormones are nearby, it suggests auto, para and intracrine mode of actions. Levels of local production changes in response to environmental stress. This local glucosteroidogenesis is essential for skin homeostasis and prevent skin pathology. Sex steroids such as androgens, estrogens and progestins are essential for a healthy skin [1, 2]. Melanocyte, which is transformed to melanoma is also under the influence of melanocyte stimulating hormone (MSH) from pituitary. Generally, melanoma is not labeled as a hormone dependent cancer because of the fact that ultraviolet (UV) rays from the Sun is the major cause for melanoma [10]. UV rays cause deoxy ribonucleic acid (DNA) damages and other inflammatory changes in the skin, which result in skin cancer [11]. About 90% of melanoma is caused by environmental factors such as UV rays, radiations and only 10% is inherited in the family. So, melanoma is never considered as a hormone dependent cancer. However, existing evidences point to a hormone relatedness to survival or a hormone responsive nature of melanoma [12, 13].

Advertisement

2. In-vitro studies from our lab

In-vitro studies from our lab showed the involvement of progesterone in the regulation of mouse and human melanoma cell growth.

2.1 Effect of Steroids on mouse melanoma (B16F10) cell growth

Initially four sex steroids viz., dehydroepiandsterone (DHEA), androstenedione (AD), testosterone (T) and progesterone (P4) were used to find out their effect on mouse melanoma (B16F10) cell growth. Though all four steroids showed a dose-dependent decrease in cell growth, yet progesterone alone showed a significant inhibition of the mouse melanoma cell growth [14].

2.2 Dose-response curves with mouse (B16F10) and human (BLM) melanoma cells

As the initial study was carried out at high concentrations (100, 150 and 200 μM). dose-response study was carried out to rule out toxic effect of steroids on melanoma cell growth inhibition. Mouse (B16F10) and human melanoma (BLM) cells showed a dose-dependent cell growth inhibition, suggesting the inhibition was a biological action and not a toxic inhibition of cell growth at high concentrations [14, 15].

2.3 Effect of related steroids on mouse melanoma cell growth

A weak androgen DHEA also inhibited mouse melanoma cell growth, but it was not as significant as the inhibition of progesterone on mouse melanoma cells. But, RU-486 a progesterone receptor antagonist and also a glucocorticoid receptor antagonist showed significant inhibition of mouse melanoma cell growth [14, 15].

2.4 Mechanism of progesterone and RU-486 actions

Since progesterone and its receptor antagonist (RU-486) showed significant inhibition on melanoma cell growth, it raised the question whether progesterone receptor was involved in this action. However, a co-incubation experiment of progesterone and RU-486 showed an additive effect on melanoma cell growth inhibition, suggesting that the action was not mediated through progesterone receptor and that each hormone acted through different mechanisms resulting in an additive effect on the inhibition of melanoma cell growth. Similarly human melanoma cell growth showed an additive effect on cell growth inhibition, when progesterone at fixed concentration (10 μM) was co-incubated with varying concentrations of RU-486 (10, 50 and 100 μM).

2.5 Dose-curve with cholesterol to check non-specific action of steroids

Since inhibition was seen with DHEA, progesterone and RU-486, it raised the question whether it was a specific effect on melanoma cell lines or common effect on all cancer cell lines? So, cells were incubated with cholesterol the parent compound of all steroids. Though, cholesterol showed initial decrease in cell growth, it failed to show a dose-dependent inhibition of cell growth. It was almost flat line from 10 μM to 200 μM, suggesting that the inhibition by progesterone and RU-486 was specific to melanoma cells.

2.6 Effect of progesterone and RU-486 on human gastric cancer cell (NUGC3) line

The effect of progesterone and RU-486 seen on mouse and human melanoma cells raised the question whether it was a non-specific effect on melanoma cell lines. So, progesterone and RU-486 were incubated separately with human gastric cancer (NUGC3) cell line. Progesterone and RU-486 did not show a significant inhibition as seen that of on melanoma cells, suggesting the inhibition was specific to melanoma cells.

2.7 Effect of progesterone and RU-486 on normal rat vascular smooth muscle cells

So far experiments were carried out on transformed cells and hence the effect on normal cells was not known. So, normal rat vascular smooth muscle cells were used. Progesterone and RU-486 were incubated with smooth muscle cells, which did not show a significant inhibition, suggesting progesterone and RU-486 inhibition were specific to melanoma cells.

2.8 Mechanism of inhibition of human melanoma cell growth

As progesterone showed a dose-dependent inhibition of human melanoma (BLM) cell growth, the mechanism of inhibition was determined. After ruling out necrosis and apoptosis, autophagy [12] as the mechanism was detected by co-incubation with 3-MA (methyl adenine) and progesterone. Results showed a partial increase in cell growth (rescue of cell growth) with 3-MA and progesterone co-incubation compared to cells incubated with progesterone alone, suggesting the mechanism of inhibition of cell growth was due to autophagy.

2.9 Other in-vitro functions inhibited by progesterone

Progesterone not only inhibited cell growth, but also other in-vitro functions such as adhesion and migration. Both adhesion and migration functions were essential for metastasis. Clinical study showed that menstruating females were better protected in melanoma in terms of increased survival and delayed metastasis than post-menopausal women and men of any age. Literature survey also revealed that progesterone level in menstruating females was 100–150 ng/ml in the follicular phase and 1000–1500 ng/dL in the luteal phase [16]. Whereas, post-menopausal females’ progesterone level was 20–100 ng/dL and males’ levels were between 27 and 90 ng/dL. The last two groups were not protected in melanoma, as per the clinical studies. In fact, progesterone in-vitro action also suggested the same. Study of progesterone effect on melanoma cells by other researchers also showed the effect of progesterone on other human melanoma cell lines. Fang et al. from China showed inhibition of A375 and A875 cell line growth by progesterone and RU-486 and that their actions were not mediated through progesterone receptor [17]. Moroni et al. [18] repeated the study with the same lines using progesterone concentrations up to 1000 μM. Kanda and Watanbe [19] already showed the inhibition of human melanoma cell growth by progesterone along with dihydrotestosterone (DHT) and estradiol (E2). However, these studies did not correlate progesterone with the protective function as reported by the clinical studies.

Advertisement

3. Summary

Progesterone, a female sex steroid significantly inhibited mouse and human melanoma cell growth significantly in-vitro. RU-486, a progesterone receptor antagonist also significantly inhibited melanoma cell growth significantly. But the action was not mediated through progesterone receptor. In addition, effect of progesterone and RU-486 were found to be not a spurious or a toxic action. In-vitro studies also showed that progesterone inhibited human melanoma cells and the mechanism of inhibition was due to autophagy. Progesterone also inhibited adhesion and migration functions (essential for metastasis) of human melanoma cells in-vitro. This observation correlated well with the previous clinical studies which reported that menstruating females were better protected (increased survival and delayed metastasis) in melanoma than post-menopausal women and men of any age. Research works around the globe also showed inhibition of human melanoma cells by progesterone. Progesterone action was mediated by the suppression of IL-8 secretion by melanoma cells.

Advertisement

4. Conclusion

As shown by the in-vitro studies, progesterone could be protecting menstruating females in melanoma. In fact progesterone could be the appropriate steroid because progesterone is anti-inflammatory in nature. Further studies from our lab showed that progesterone suppressed pro-inflammatory cytokine IL-8 [20]. In fact, progesterone could be the appropriate steroid because progesterone is anti-inflammatory in nature. So, progesterone action could be mediated by the suppression of pro-inflammatory cytokine IL-8, which decreased melanoma cell growth in-vitro. Hence, survival of menstruating females in melanoma may be dependent on progesterone. So, progesterone apart from its effect on reproduction has also a role in protecting females from melanoma.

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Pandurangan Ramaraj (December 2nd 2021). A Review of Progesterone Effects on Human Melanoma Cell Growth In-Vitro, Global Women's Health, Zhengchao Wang, IntechOpen, DOI: 10.5772/intechopen.101239. Available from:

chapter statistics

51total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Regulation of Exosomes in the Pathogenesis of Breast Cancer

By Congjian Shi, Hongqin Yang, Zhengchao Wang and Zhenghong Zhang

Related Book

First chapter

Clinical Features of PCOS

By Bassim Alsadi

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us